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Abstract
Background: Congenital heart disease (CHD) occurs in almost 1% of newborn children and is considered a
multifactorial disorder. CHD may segregate in families due to significant contribution of genetic factors in the
disease etiology. The aim of the study was to identify pathophysiological mechanisms in families segregating CHD.
Methods: We used whole exome sequencing to identify rare genetic variants in ninety consenting participants
from 32 Danish families with recurrent CHD. We applied a systems biology approach to identify developmental
mechanisms influenced by accumulation of rare variants. We used an independent cohort of 714 CHD cases and
4922 controls for replication and performed functional investigations using zebrafish as in vivo model.
Results: We identified 1785 genes, in which rare alleles were shared between affected individuals within a family.
These genes were enriched for known cardiac developmental genes, and 218 of these genes were mutated in
more than one family. Our analysis revealed a functional cluster, enriched for proteins with a known participation in
calcium signaling. Replication in an independent cohort confirmed increased mutation burden of calcium-signaling
genes in CHD patients. Functional investigation of zebrafish orthologues of ITPR1, PLCB2, and ADCY2 verified a role
in cardiac development and suggests a combinatorial effect of inactivation of these genes.
Conclusions: The study identifies abnormal calcium signaling as a novel pathophysiological mechanism in human
CHD and confirms the complex genetic architecture underlying CHD.
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Background
Congenital heart disease (CHD) represents malforma-
tions of the heart or intra-thoracic vessels, which affect
cardiac function and occur in almost 1% of live births
[1]. Most patients survive until adulthood, and the num-
ber of adults with CHD has increased to above 3 million
in Europe and the USA alone [2]. These patients are
challenged by serious cardiovascular complications,
which require specialized care, and their children have
significantly increased CHD risk [3].
Although the specific cause of CHD is unknown for
most patients, genetic factors contribute significantly to
the etiology (reviewed in [3, 4]).
Families presenting with recurrent cases suggest that
mutations with large effects segregate with CHD in such
families. Recent targeted next generation sequencing
(NGS) efforts have shown that causative mutations may
be identified in one third of CHD families [5]. In the ma-
jority of familial cases, the unidentified pathogenic vari-
ants may be explained by a “burden of genetic variation”
model, which hypothesizes that CHD may occur if the
developing embryo is exposed to a certain burden of rare
and common genetic variants, possibly in combination
with epigenetic, environmental, or stochastic effects [4].
Genomic information obtained by NGS analyses may
further clarify genetic and molecular mechanisms caus-
ing CHD and thus contribute to improved health care
and counseling of the patients and families. However,
because of the complex genetic architecture of CHD,
more sophisticated methods for interpretation of genetic
variation need to be developed before such information
may be translated into clinical use.
Here, we performed whole exome sequencing (WES)
in a cohort of 32 Danish families in which several family
members presented with CHD. Utilizing a systems biol-
ogy approach, we discovered recurrent mutation of
genes involved in calcium signaling. Loss-of-function
analyses of three of the genes confirmed their crucial
role in embryonic heart development.
Methods
Patient material
CHD families were identified through the Danish Na-
tional Patient Registry (DNPR) and contacted by letter.
Clinical diagnoses were validated by manual review of
the patient files, and detailed pedigrees were constructed
based on interview with patients (Additional file 1: Fig.
S1). There was no known consanguinity in the families.
All family members presenting with CHD were non-
syndromic, except III.1 in family 545, who had a diagno-
sis of Turner syndrome. Cardiac malformations are
listed below affected family members in Additional file 1:
Fig. S1. The age at diagnosis of affected family members
ranged from 1 day to 65 years (median age, 1 year; Q1,
29 days; Q3, 8 years). Clinical evaluation for CHD was
not performed on asymptomatic family members. Ter-
mination of pregnancy was performed in fewer than 5
cases (data not shown).
DNA samples were obtained from a cohort consisting
of 90 individuals in 32 families. Affected family members
were not screened for 22q11 deletions, but index pa-
tients were screened for mutations in the NKX2-5 gene
prior to WES. A frameshift mutation (c.112delG) was
found to segregate with ASD in a single family [6]. This
family was excluded from the cohort prior to exome
sequencing.
Relatedness of family members was determined using
the algorithm implemented in VCFtools. Pairwise re-
latedness of all 90 individuals is shown in Add-
itional file 1: Fig. S2A. Relatedness between individuals
not belonging to the same family peaks around zero,
confirming that the families are unrelated. Individuals
within families have positive relatedness score, confirm-
ing that they are related (Additional file 1: Fig. S2B).
The self-reported ethnicity of the individuals in our
cohort was Danish. To verify the ethnic homogeneity of
the 90 samples, we used the algorithm for detection of
outliers implemented in PLINK. For each individual in
our cohort, we calculated the population distance to the
20 nearest neighbors using an identity-by-state (IBS)
matrix based on 208,163 variants. These distances were
compared to the mean of the population in terms of
standard deviations (Z-scores). This test showed that no
samples had Z-scores below − 2.5 confirming the ethnic
homogeneity of the samples (Additional file 1: Fig. S3).
Principal component analysis (PCA) was performed
using FlashPCA (https://github.com/gabraham/flashpca).
PCA was based on a selected set of common (MAF >
5%) high-quality genetic variants that overlap with the
1000 Genomes data [7]. The Danish samples which were
analyzed together with reference samples of different
Super Populations from 1000 Genomes appear similar to
European populations (Additional file 1: Fig. S4). We
identified one outlier sample, but this particular individ-
ual had two siblings with similar type of CHD and was
not excluded from the study.
Whole exome sequencing
Ninety exomes corresponding to 79 patients and 11 obli-
gate carriers were sequenced. Capture followed the
protocol corresponding to an Agilent Sure Select exome
v4 kit, and 100-bp paired-end sequencing reads were
generated on an Illumina Hiseq 2000 machine. Both ex-
ome capture and sequencing were performed at BGI
Europe’s facility in Copenhagen. The average sequencing
coverage was 91.8×. Eighty-six percent of the samples
had a sequence coverage of 30× or higher in 80% of the
exome. Cumulative sequencing coverage is shown in
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Additional file 1: Fig. S5A. Mean number of sequencing
reads per sample was 64,396,134 (range 47,821,039–85,
327,021). The distribution of sequencing reads is shown
in Additional file 1: Fig. S5B.
Variants were stored in a mySQL database to facilitate
filtering and comparison between both individuals and
families. Population-wide allele frequencies were used to
remove variants with a minor allele frequency higher
than 1%. Finally, variants with unclear impact on gene
function were removed (see definitions below).
Bioinformatics pipeline for variant calling
Bioinformatics analysis of the sequencing data followed
standard practices in the field and included assessment
of data quality with FastQC; mapping to the human ref-
erence genome (hg19/Grhc37) with BWA mem [8]; re-
moval of PCR duplicates, local indel realignment, base
quality score recalibration, and variant calling with Hap-
lotypeCaller were performed with GATK [9]. Only vari-
ants with Phred scores ≥ 30 were considered. The
functional consequences of variants were assessed with
Ensembl’s Variant Effect Predictor (VEP) tool [10]. This
step included the prediction of the pathogenicity of iden-
tified variants with both SIFT [11] and Polyphen-2 [12].
Variants were stored in a mySQL database to facilitate
filtering and comparison between both individuals and
families.
Filtering of variants
Following genotype calling, variants were filtered to
meet a number of sequencing quality requirements prior
to consideration. The variants should correspond to sin-
gle nucleotide events both in the reference and alterna-
tive alleles, be supported by read depth of at least 30 at
the genomic position, and have a Phred call quality
greater than 30. Similarly, variants were required to be
present in all affected members of a family, either in het-
erozygosity or in homozygosity.
Population-wide allele frequencies were used to fur-
ther filter the candidate variants under the prerogative
that the observed incidence of CHD is not coherent with
highly frequent variants being causative factors. Variants
were filtered from our analysis if they were observed
with a minor allele frequency (MAF) higher than 1% in
either any of the main populations (AFR, AMR, ASN,
CEU) comprised by the 1000 Genomes (1000G) project
[7], the catalog of Exome Annotation Consortium [13]
(ExAC), or its European (non-Finnish) subpopulation.
Similarly, we exploited the Danish ancestry of the pa-
tients for further reduction of the number of candidate
variants. First, we discarded from further analyzing those
variants with MAFs higher than 1% in 2000 Danish
exomes [14]. Second, variants present in 5% of the alleles
of the 100 parents included in the Genome Denmark
cohort [15, 16] were excluded in further analyses. This
step implied a lift-over [17] of variants between the co-
ordinates of reference genomes hg38 and hg19; in cases
where multiple variants remapped to the same genomic
position, the highest allele frequency for each possible
allele was considered.
A final filtering exploited the functional consequences
of variants according to affected genomic elements. Vari-
ants with unclear impact on gene function were disre-
garded. These included all noncoding variants (except
intronic variants in splice sites), stop codon variants
where the stop codon is retained, and nonsense-
mediated decay (NMD) transcript variants.
We did not filter variants according to in silico predic-
tion of functional consequence (e.g., Polyphen or SIFT
scores).
Enrichment of known CHD genes
We curated two lists of known CHD genes. A list of 829
genes which cause CHD when mutated in mice was de-
rived from data in the Mouse Genome Informatics data-
base (Additional file 1: Table S1). A list of 144 human
CHD disease genes was curated from the literature
(Additional file 1: Table S2). Statistical significance of
overlaps was calculated using one-tailed Fisher’s exact
test, with a significance level of p < 0.05.
Definition of enriched protein-protein interaction
modules
Protein-protein interactions (PPIs) were obtained from
InWeb (InWeb5.5rc3), a scored high-confidence PPI
database which contains 87% of human proteins and
more than 500,000 interactions [18]. PPIs were repre-
sented as a network; nodes represent proteins and edges
represent interactions between these proteins. InWeb
contains protein interactions for 1310 of the 1785 candi-
date genes identified in our families. We used data from
InWeb to generate a PPI network of these 1310 genes
and their first-degree interactors. The PPI network was
pruned to include only high-confidence relationships; we
disregarded high-throughput yeast-2-hybrid experiments
(“Matrix” interactions according to InWeb’s termin-
ology) and interactions with a confidence below 0.1.
After confidence filtering, the PPI network included a
total of 8186 genes and 29,463 high-quality interactions.
The PPI network was partitioned into overlapping
modules (clusters) with ClusterOne [19] using the confi-
dence score derived from InWeb to weight the cluster-
ing. Clusters were considered significant when below a
corrected (Benjamini-Hochberg FDR method) one-sided
p value of 0.05 and a minimum of five proteins. Highly
connected clusters of proteins identified in this fashion
constitute a proxy for functionally related protein
complexes.
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Enrichment of candidate genes was determined for
each cluster by permutation analysis (k = 10e4) using
random clusters of comparable size. Correction for mul-
tiple testing was performed using the procedure of
Bonferroni-Holm. A one-sided p value of 0.05 was used
as significance level to identify clusters significantly
enriched for candidate genes.
Probability of being loss-of-function intolerant (pLI)
values of genes encoding the 27 proteins in the calcium-
signaling module, 829 and 144 known CHD genes from
mouse models and patients, respectively, was obtained
from the ExAC database. The distributions were com-
pared to all 18,225 genes listed in the ExAC database
using a Kruskal-Wallis one-way analysis of variance on
ranks. Significance level was 0.05.
Replication
WES data from a previously published, independent co-
hort was used for replication, please see Sifrim et al. for
details [20]; WES data from a total of 714 non-
syndromic CHD cases and 4922 controls of European
ancestry was analyzed.
Control samples were participants in the INTERVAL
randomized controlled trial which were recruited with
the active collaboration of NHS Blood and Transplant
England, which has supported fieldwork and other ele-
ments of the trial. DNA extraction and genotyping were
funded by the National Institute of Health Research
(NIHR), the NIHR BioResource, and the NIHR
Cambridge Biomedical Research Centre. The academic
coordinating center for INTERVAL was supported by
core funding from the NIHR Blood and Transplant Re-
search Unit in Donor Health and Genomics, UK Medical
Research Council (G0800270), British Heart Foundation
(SP/09/002), and NIHR Research Cambridge Biomedical
Research Centre.
Replication was performed by comparing the number
of cases and controls harboring very rare (MAF < 0.001)
variants in any of the genes ADCY2, ADCY5, CACN
A1D, CACNA1H, CACNA1I, CACNA1S, GRIA4, ITPR1,
NFAT5, and PLCB2. Data from CACNA1F was missing;
thus, this gene was excluded from the analysis. The
MAF cutoff (0.001) was chosen by performing a burden
test for synonymous variants in 10,000 random sets of
genes of the same size as the set above (two-sided Fish-
er’s exact test). For two different scenarios (MAF < 0.01
and MAF < 0.001), we observed a better match between
expected vs. observed p values using MAF < 0.001 (Add-
itional file 1: Fig. S12).
Synonymous variants, protein altering variants (PAV)
(inframe_insertion, start_lost, stop_retained, stop_lost,
missense, inframe_deletion, protein_altering, start_
retained), and protein truncating variants (PTV) (stop_
gained, splice_donor, splice_acceptor, frameshift) were
identified using the Variant Effect Predictor tool (VEP
API v90). Quality control and filtering were performed
using Hail 0.2. In brief, both samples and variants were
included for further analysis if they met the following fil-
tering criteria: call rate ≥ 0.95, genotype quality average ≥
25, and depth average ≥ 15. In addition, only genotypes
(heterozygous) with allelic balance (AB) within the range
0.25–0.75 were retained in the analysis. Deleterious vari-
ants were identified by assigning a Combined Annota-
tion Dependent Depletion (CADD) score [21] and a
score based on regional missense constraint (MPC
score) [22]. MPC score > 2 was used to identify patho-
genic variants. Previous analysis of de novo variants
identified in 5620 cases with neurodevelopmental disor-
ders shoved that variants with MPC > 2 have a rate 5.79
times higher in cases than controls. Statistical signifi-
cance was calculated using two-tailed Fisher’s exact test,
with a significance level of p < 0.05.
To test the specificity of the observed burden of rare
variants, we created 10,000 random sets of 10 genes with
the same size distribution as the gene set of 10 calcium-
signaling genes, which were analyzed in the replication
study. For each of the 10,000 random gene sets, we
counted the number of cases with pathogenic variants
(MPC score > 2).
Zebrafish maintenance and microinjection
AB/TL zebrafish strain (obtained from the Zebrafish
International Resource Center) was used in the experi-
ments. Embryos were maintained and staged as previously




CAG-3′), and standard-MO (5′-CCTCTTACCTCAGT
TACAATTTATA-3′) and 0.5, 1, and 2 ng of adcy2a-SP-
MO2 (5′-CCCCCAGTCTCCAAACACTCACCAG-3′),
itpr1b-SP-MO2 (5′-CCAGACTGTAGACAAGAGAGAC
ATG-3′), and plcb2-SP-MO2 (5′-TGTGGTAAAGGATA
CTCCACCCAGT-3′) (Gene Tools, LLC) were injected
into one-cell stage embryos and harvested at 48 hpf. Em-
bryos were imaged under Zeiss AxioZoom V16 (Carl
Zeiss, Brock Michelsen A/S, Denmark).
In order to verify SP-MO efficiencies, embryos injected
with SP-MOs were collected at 48 hpf and RNA was iso-
lated by QIAzol reagent (Qiagen). cDNA synthesis was
performed using iScript Reverse Transcription Supermix
(Bio-Rad). SP-MO knockdown was assessed by PCR
using gene-specific primers (Additional file 1: Table S3)
spanning the SP-MO-targeted exon.
Whole-mount in situ hybridization
Digoxigenin (DIG)-labeled anti-sense myl7 and mef2cb
[25] riboprobes were synthesized from linearized pGEM-
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T easy and pCMV-SPORT6.1 vectors respectively using
the DIG RNA labeling mix (Roche) and the T7 RNA poly-
merase (Roche). Embryos collected at 48 hpf were raised
in the presence of 0.2 mM 1-phenyl-2-thiourea (PTU)
upon gastrulation for optical clarity [24]. For analysis of
myl7 and mef2cb expression, embryos at 48 hpf and 10 so-
mite stages, respectively, were dechorionated and fixed in
freshly prepared 4% paraformaldehyde in phosphate-
buffered saline (PBS, pH 7.4) overnight. Whole-mount in
situ hybridization was performed as previously described
with minor modifications [26]. Embryos were imaged
under Zeiss AxioZoom V16 (Carl Zeiss, Brock Michelsen
A/S, Denmark). The staining intensity of mef2cb ribop-
robe was measured as integrated density (IntDen, ImageJ
software-NIH, USA), and mean values from three em-
bryos of each group were plotted relative to wild-type
value. Data were shown as mean ± std dev.
Real-time quantitative RT-PCR
Total RNA from pools of 50 zebrafish embryos was ex-
tracted using TRIzol (Ambion) and a RNeasy mini kit
(Qiagen) and used to synthesize random-primed cDNA
(SuperScript II Reverse Transcriptase, Invitrogen). A
Brilliant III Ultra-Fast SYBR® Green QPCR Master Mix
(Agilent Technologies) was used for cDNA amplifica-
tion. Samples were analyzed using a 7500 fast real-time
PCR system (Applied Biosystems). Data were normalized
to the average expression of housekeeping genes actb1
and rpl13a. RT-PCR primers are listed in Add-
itional file 1: Table S3.
Results
Exome sequencing data analysis
We performed whole exome sequencing of 90 individ-
uals belonging to 32 multiplex CHD families (Add-
itional file 1: Figs. S1-S4). To identify potentially
disease-causing genes, we analyzed rare variants
shared by affected family members. The analysis was
performed after removing the variants that are likely
sequencing artifacts, that occupy genomic elements
with a mild functional consequence, or that can be
found widespread in the general population (see the
“Methods” section, workflow shown in Additional file 1:
Fig. S6). We identified 3698 rare inherited variants in
1785 genes, denoted candidate disease genes (CDGs)
hereafter. The number of CDGs per family ranged
from 56 to 507 (Additional file 1: Fig. S7).
Recurrent candidate disease genes
To test if particular candidate genes were overrepresented,
we calculated the fraction of CDGs shared by all possible
pairs of families in the cohort (Fig. 1a, Additional file 1: Fig.
S8). Pairs of families only share a small fraction of their
CDGs (median = 0.05, 72.3% of pairwise values < 0.2).
To analyze this in more detail, we calculated the num-
ber of families with rare inherited variants in each of the
1785 CDGs. None of the 1785 CDGs was mutated in
more than seven families (Fig. 1b, Additional file 1: Fig.
S9) after disregarding genes that rely on the accumula-
tion of variants to exert their biological function, like
hypermutated genes in the MHC machinery or genes
encoding olfactory receptors.
We identified 218 CDGs shared between two or more
families. For variants shared between two and three fam-
ilies, less than 20% were identical across families (Fig. 1c,
d). We propose that these variants might partially ex-
plain the origin of the disease. For example, three differ-
ent rare alleles of DNAH5 were identified in affected
members of families 489, 732, and 1121, where patients
presented with ASD, VSD, and outflow tract defects.
Mutation of DNAH5 is associated with primary ciliary
dyskinesia (PCD, OMIM #608644) [27]. A subset of
PCD patients present with CHD [28]. Another example
of a CDG where rare variants were found in more than
one family is KMT2D, which encodes a histone methyl
transferase involved in heart development [29]. Mutation
of KMT2D is associated with Kabuki syndrome (OMIM
#147920), a rare developmental disorder which includes
CHD as part of a wide phenotypical spectrum [30].
CDGs are enriched for known disease genes
We expect that a subgroup of variants in our 1785
CDGs could be causative mutations leading to CHD. In
such a scenario, a diverse but limited number of gen-
omic variants, acting by the accumulation of additive ef-
fects, could explain the occurrence of CHD in individual
families. This etiological diversity at the genomic level
would hinder detection with traditional association ana-
lysis, but we hypothesized that the CDGs would be
enriched for known CHD disease genes. To test this, we
calculated the overlap between the 1785 CDGs in our
families and curated lists of genes known to cause CHD
in mouse models and patients, when mutated (Add-
itional file 1: Table S1 and S2). We observed significant
enrichment of known CHD genes among CDGs affect-
ing five or fewer families (Fig. 2a, b). When only variants
scored pathogenic by SIFT/Polyphen-2 are considered,
this enrichment increases Additional file 1: Fig. S10). In
order to validate the CDG list and explore the possibility
of a selection bias in our sets of known CHD genes, we
produced 10,000 random gene sets (one for each of the
two sets) and ascertained the overlap with the CDGs.
This analysis corroborated the statistical significance of
the observations (p value< 0.0001 for both sets).
Distribution of known CHD genes across families is
shown in Additional file 1: Fig. S11 and Additional file 1:
Table S4. Individual families often present with rare mu-
tations in more than one known CHD gene, suggesting a
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substantial fraction of the observed heart defects might
be explained by a combination of rare mutations inher-
ited within the families. Under the hypothesis that CHD
runs within individual families as the result of such a
combined effect from mutations in several developmen-
tal genes, we would expect that families present signifi-
cant enrichment of mutations harbored by known CHD
genes. Enrichment of CHD genes from mouse models
per family was determined using a permutation test (n =
10,000). Affected individuals from 23 families share rare
mutations in known CHD genes. In 19 of these 23 fam-
ilies (78.3%), enrichment of known CHD genes among
the CDGs is statistically significant at p < 0.05 (Fig. 2c).
For comparison, we filtered our variants following the
strategy, recently applied by Bayrak et al. [31]. In this ap-
proach, we only included variants, shared between at
least two affected individuals per family and with popu-
lation MAF < 0.001 (across all GenomAD populations
and in the GenomAD European, not Finnish
population). In addition, genes with a Gene Damage
Index (http://lab.rockefeller.edu/casanova/GDI) predic-
tion of “high” were removed from the list of CDGs. With
this approach, we identified a total of 719 variants in 577
genes. When we compared with our curated lists of
CHD genes in mouse models and patients (Add-
itional file 1: Table S1 and S2), we identified 36 CDGs
overlapping with mouse CHD genes and five CDGs
overlapping with human CHD genes. However, the over-
laps were not statistically significant (p = 0.1406 and
0.8178, respectively, Fisher’s exact test), suggesting that
very stringent filtering removes a significant number of
causative variants.
Rare variants affect functional modules in a protein-
protein interaction network
We further investigated whether CHD was caused by
the disruption of cooperative protein functionality at the
systems level rather than at the individual gene level. A
Fig. 1 Distribution of candidate disease genes and variants across families. a Overlap between CDGs in pairs of families. b Distribution of CDGs
across families. The number of CDGs found in one, two, three, and 4–7 families is shown. c Distribution of alleles in CDGs found in three families
(1-2-3, three different alleles; 1-1-2, two different alleles; 1-1-1, same allele found in all three families). d Distribution of alleles in CDGs shared in
two families (1-2, different alleles; 1-1, same allele).
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protein-protein interaction network was generated using
1310 seed genes (the subset of the 1785 CDGs for which
InWeb has recorded protein interactions). Their first-
degree neighbors and their interactions from the current
version of InWeb (InWeb5.5rc3) [18] were added as
well, summing up to a total of 8186 proteins and 29,463
interactions. Using the graph clustering algorithm Clus-
terOne [19], we identified 230 significant PPI clusters
considering a threshold p value of 0.05 and a minimum
number of five genes. Of these, 25 clusters presented
two or more genes mutated in at least one of the fam-
ilies (Additional file 1: Table S5). By permutation ana-
lysis (k = 10,000), we identified two clusters
accommodating more CDGs than expected by chance (p
values of 0.039 and 0.0033, respectively).
One of these corresponds to a small module, encoded
by of five genes (INSL1, RXFP2, RLN1, RLN2, RXFP1)
where the three first are CDGs. Due to the small size
and low connectivity of this cluster, we decided to focus
on the second cluster.
The second significant cluster corresponds to a highly
interconnected group of 27 proteins, encoded by eleven
CDGs and their first-degree interaction partners (Fig. 3a).
These CDGs present mutations in ten different families.
Affected individuals from three families shared rare mu-
tations in more than one of the eleven genes, and two
genes (ITPR1 and CACNA1S) were each mutated in two
different families (Additional file 1: Table S6).
The 27 proteins in the cluster constitute calcium chan-
nels or signal transduction enzymes such as adenylate
cyclase that interacts with calcium-dependent protein ki-
nases. A Gene Ontology term enrichment analysis using
AmiGO [32] for the 27 proteins in the cluster showed
enrichment in biological processes involved in calcium
signaling (Additional file 1: Table S7).
To investigate the functional importance of the genes
encoding proteins in the cluster, we compared the prob-
ability of being loss-of-function intolerant (pLI) of these
27 genes with known CHD genes and all 18,225 genes
listed in the Exome Aggregation Consortium database.
The distributions of pLI scores of known CHD genes
have median pLI values of 0.63 and 0.86, respectively,
and the distributions suggest that more than half of
known CHD genes are intolerant against loss-of-
function mutations (Fig. 3b). The distribution of pLI
scores of the 27 genes encoding proteins in the signifi-
cant cluster is skewed towards the higher values of the
distribution (median = 0.98), suggesting intolerance to
loss-of-function mutations and supporting the hypoth-
esis that these genes might potentially play an active role
in the etiology of CHD.
Replication
Using WES data from an independent cohort of 714
CHD cases and 4922 controls [20], we tested the mu-
tation burden of the same calcium-signaling gene set,
as we found mutated in our families (genes listed in
Additional file 1: Table S6). In this gene set, we ana-
lyzed the distribution of CADD and MPC variant
scores between CHD cases and controls, and observed
significant different score distributions of rare (MAF <
0.001) variants, predicted to alter the gene products
(i.e., PAV and PTV) (Fig. 4). Variants with MPC score
above 2 (MPC2 variants) have been shown to be
Fig. 2 Enrichment of CHD genes in candidate disease genes. Overlap between CDGs and known CHD genes from mouse models (a) and
patients (b). The number of overlapping genes is plotted against the number of families the CDGs were found in. c The number of overlapping
genes (mouse models) per family. Statistical significance of the overlap is indicated by color code (red colors, significant; gray color, not
significant (n.s.))
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significantly associated with pathogenesis [22]. Thus,
to test for burden of pathogenic mutations, we calcu-
lated the number of cases and controls harboring
MPC2 variants in the calcium-signaling gene set. We
observed more than 2-fold enrichment (OR 2.68, p
value 3.7e−04) of such variants in CHD cases (Add-
itional file 1: Table S8). To test if this enrichment
was specific for the calcium-signaling gene set, we
created 10,000 random gene set with the same size
distribution as the calcium genes. For each random
set, we counted the number of CHD cases harboring
MPC2 variants. Only four of the random gene sets
were found with more MPC2 variants in cases than
the calcium gene set (Additional file 1: Fig. S13).
Fig. 3 Identification of a calcium-signaling network affected by rare mutations identified in CHD families. a Network module of CDGs (blue) and
their interaction partners (gray). The module accommodates more CDGs than expected by chance (adjusted p value 0.0033). Proteins are shown
as hexagons; protein interactions are shown with lines. b Violin plots of distributions of pLI scores in genes encoding the 27 proteins in the
network module (upper, blue), known CHD genes from patients and mouse models (middle, red and pink, respectively), and all 18,225 genes
listed in ExAC with a calculated pLI score (lower, gray).***p < 0.001. ns, not significant (Kruskal-Wallis one-way analysis of variance on ranks)
Fig. 4 Distribution of MPC and CADD scores of rare variants in 714 CHD cases and 4922 controls. Protein altering and truncating variants (PAV
and PTV) with MAF < 0.001 identified in the genes ADCY2, ADCY5, CACNA1D, CACNA1H, CACNA1I, CACNA1S, GRIA4, ITPR1, NFAT5, and PLCB2 were
scored using MPC score [22] (a) or CADD score [21] (b). NCHD = 136 variants. NControls = 982 variants. Difference between median values of controls
and cases was determined using a Mann-Whitney rank-sum test. **p < 0.01, *p < 0.05
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These results confirm an increased burden of patho-
genic mutations in genes involved in calcium signal-
ing among CHD patients.
Knockdown of adcy2a, itpr1b, and plcb2 causes cardiac
malformations in zebrafish
We used zebrafish as a model to address the functional
relevance in heart development, of genes within the
identified cluster. In the cluster, 11 out of 27 genes were
mutated in the families we assessed. From these 11
genes, we assessed the consequence of loss-of-function
for three zebrafish genes, adcy2a, itpr1b, and plcb2.
These genes are orthologues to the human genes
ADCY2, ITPR1, and PLCB2, encoding calcium-signaling
proteins, of which roles in cardiac development have
been elusive.
We found that knockdown of either of the three
genes by morpholino oligonucleotides gave rise to ab-
normal morphology or laterality of the heart (Fig. 5a).
The abnormal morphology included aberrant atrio-
ventricular canal (AVC) formation where the ring
structure of AVC was hindered, mis-looping of the
heart, and narrowing in the atrium or ventricle. Lat-
erality defects reflected straight or reversed hearts. In-
jection of adcy2a-MO, itpr1b-MO, and plcb2-MO
resulted in cardiac defects in 53%, 73%, and 66% of
embryos, respectively (Fig. 5b).
In addition to the cardiac defects, knockdown of itpr1b
caused edema in the brain, whereas curved tail was seen
by knockdown of plcb2 (Fig. 5a).
Knockdown of more than one gene by injections of
both efficient and sub-efficient doses of MO resulted in
an increase of the number of embryos with heart defects,
suggesting a combinatorial effect (Fig. 5b, Add-
itional file 1: Fig. S14).
We showed that the morpholinos work efficiently
causing splicing defects (Additional file 1: Fig. S15), and
we validated the specificity of the morpholinos, by using
a second set of morpholinos and co-injection of in vitro
expressed mRNAs encoding wild-type proteins (Fig. 5b,
Additional file 1: Fig. S15). Unfortunately, we were not
able to clone the cDNA of itpr1b, presumably due to the
large size of the transcript (8.4 kbp coding region), but
co-injection of wild-type adcy2a and plcb2 mRNA re-
sulted in partial rescue of the cardiac phenotype, con-
firming the specificity of the morpholinos.
To investigate effects of gene knockdown at the mo-
lecular level, we analyzed the expression of mef2c, a
transcription factor which is involved in cardiac mor-
phogenesis and myogenesis and known to be a specific
Fig. 5 Functional validation of candidate genes in zebrafish. a Phenotype of controls and morphants. Single genes and combinations of genes
targeted by splicing morpholinos are indicated on the left. Upper panels: gross appearance of 48 hpf zebrafish embryos. Lower panel: examples
of cardiac phenotypes of 48 hpf wt, control, and morphant embryos. Hearts were visualized by ISH with a probe against the cardiac marker myl7.
b Quantification of phenotypes in wt, controls, morphants, and mRNA rescued morphants. Note the combinatorial effects on cardiac phenotypes
when more than one gene is affected. c, d Expression of mef2cb in 10 somite stage zebrafish embryos, analyzed by qRT-PCR (c) and ISH (d). ISH
staining intensity was quantified and analyzed using Student’s T test. *p < 0.05, **p < 0.01
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target for Ca2+-dependent control of gene expression in
cardiomyocytes [33, 34]. In zebrafish, two copies of
mef2c exist. We analyzed the expression of mef2ca and
mef2cb in wild-type, control, and morphant embryos at
10 somite stages, where both genes are expressed in the
bilateral heart fields at the anterior lateral plate meso-
derm. We observed significantly reduced expression of
mef2cb in adcy2a, itpr1b, and plcb2 morphants (Fig. 5c,
d).
Discussion
Interpretation of variants detected in exomes from CHD
patients is challenging due to the extreme heterogeneity
which characterize CHD [4]. Analysis of complex net-
works has previously been applied successfully to inter-
pret genetic variants [31, 35–38]. Such analyses often
use stringent variant filtering criteria to identify candi-
date genes, followed by network analysis to interpret
biological function. Here, we present an alternative ap-
proach, based on lenient filtering of variants, followed by
stringent network analysis using a high-confidence hu-
man PPI network [18].
We analyzed the exomes of 90 individuals in 32 multi-
plex CHD families for rare variants, which were shared
among affected individuals within a family. Considering
that CHD rarely has a monogenic cause, but may be
caused by a burden of rare and common genetic vari-
ants, we selected an arbitrary filtering threshold of MAF
above 0.01 and we did not filter the variants for in silico
predictions of consequence. We expect that our filtering
has removed a significant amount of neutral variants,
while keeping possible variants with medium to strong
effects. However, it is likely that we also have removed a
number of causative variants by applying this criterion,
as well as our focus on the exome limits the number of
possible causative variants identified in our study.
We identified 1785 candidate disease genes. The large
number of candidate genes is partly a consequence of
our non-stringent filtering strategy and underlines the
challenge in interpreting variants in CHD patients, even
in multiplex families. However, our analysis showed that
the 1785 CDGs were enriched for genes known to cause
heart defects and that application of very stringent filter-
ing conditions removes a significant part of causative
variants.
Approximately 12% of the CDGs were found in more
than one family, but none of them was represented in
more than seven families, and on average, less than 10%
of the CDGs found in a family were shared with another
family. Thus, our data support that CHD is an extremely
heterogeneous disorder and consistent with a model,
where several rare genetic variants contribute to the
pathogenesis in the individual patient. However, we do
not expect that all of our CDGs are true CHD disease
genes; thus, a significant proportion of the rare variants,
which are shared by affected individuals, may be of lim-
ited functional consequence.
To identify pathophysiological mechanisms associated
with CHD, we integrated PPI data in our analysis of
CDGs and discovered that eleven of the CDGs converge
in a functional cluster of genes, which encode proteins
involved in calcium signaling. Analysis of an independ-
ent case-control cohort confirmed increased mutation
burden of this calcium-signaling gene set in CHD pa-
tients, thus supporting that defects in calcium signaling
are associated with CHD.
Intracellular calcium plays essential roles in physiology
and pathophysiology of the adult heart. In the healthy
heart, intracellular calcium fluxes control cardiomyocyte
contraction and mutations in calcium-handling genes
may cause arrhythmia [39]. In addition, calcium also
modulates transcription in cardiomyocytes through a
complex signaling network, and abnormal calcium hand-
ling and signaling are part of the pathophysiology in
congestive heart failure [33, 40].
Defects in calcium signaling have not previously been
associated with CHD in humans, but animal studies im-
plicate an important role of calcium signaling in heart
development. Targeted deletion of Nfatc1is embryonic
lethal in mice and causes malformation of the cardiac
valves, outflow tract, and ventricular septum [41, 42].
Overexpression of activated calcineurin rescues cardiac
developmental defects in calreticulin-deficient mice [43].
Pharmacological blockade of L-type calcium channels
during embryonic development causes heart defects in
mice [44]. However, epidemiological studies show that
therapeutic doses of calcium channel blockers have very
low teratogenicity [45, 46].
Two of the 27 proteins within the cluster we identified
were previously implicated in cardiac development and
CHD. Knockout of Nfat5 is embryonic lethal in mice
and results in reduced compaction of cardiomyocytes in
the ventricular wall and trabeculae [47]. Double knock-
out of Itpr1 and Itpr3 results in aberrant development of
the outflow tract and right ventricle, while mice defect-
ive of only one of the two genes develop normally [48].
Likewise, double knockout of Itpr1 and Itpr2 is embry-
onic lethal and results in cardiac malformation [49], to-
gether suggesting a redundant role of IP3 receptors in
mammalian heart development.
Analysis of embryonic mice has shown that NFAT5
and IP3 receptors are expressed in the heart during em-
bryonic development, but also in several other tissues
[47–49]. Similarly, many well-characterized CHD genes
are also expressed in extra-cardiac embryonic tissues,
and some of these genes have been associated with both
isolated and syndromic forms of CHD [3, 50]. Thus, fu-
ture detailed genotype-phenotype analyses of CHD
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disease genes may be useful for further dissection of em-
bryonic developmental mechanisms.
Functional validation of ADCY2, ITPR1, and PLCB2 in
a zebrafish model confirmed a critical role during em-
bryonic heart development. We observed defects in car-
diac morphology and laterality in a significant
proportion of embryos injected with morpholinos target-
ing adcy2a, itpr1b, and plcb2. Importantly, we observed
more embryos with cardiac defects when combinations
of two and all three genes were knocked down, support-
ing that the three genes interact functionally in heart de-
velopment. Specificity of the morpholinos used in the
experiments was confirmed by rescue experiments and
further corroborated by significant reduction in the ex-
pression of mef2cb, a zebrafish orthologue of Mef2c,
which is a well-established target of calcium signaling in
cardiomyocytes [48, 51]. Thus, the results of the zebra-
fish experiments support the hypothesis that expression
and interaction of the three genes play important roles
in heart development. However, it is important to note
that depletion of the gene products precipitated by mor-
pholino injections in zebrafish does not represent a true
model of the molecular pathology of CHD in affected
family members. Firstly, the majority of mutations,
which we identified in calcium-signaling genes, were
missense mutations and carriers were all heterozygous.
Thus, we do not know if the effects of the mutations
were haploinsufficiency or gain-of-function. And second,
it is possible that factors other than calcium-signaling
genes may play a role in the molecular pathology of indi-
vidual patients.
The cardiac malformations, present in our family co-
hort and replication cohort, were unselected with re-
spect to severity or anatomical similarity. Thus, our data
indicate that calcium-signaling defects are associated
with both familial and sporadic CHD and unrelated to
specific groups of malformations.
We have recently shown that specific malformations
co-occur in families, suggesting that specific develop-
mental programs may be responsible for certain groups
of heart malformations [52]. We suggest that WES or
whole genome sequencing of cohorts of families selected
for specific malformations, combined with systems-
based analysis, as presented here, may be a useful strat-
egy for identification of pathophysiological mechanisms
in CHD.
Conclusions
Our data support a model where CHD is caused by a
combinatorial effect of rare and common genetic vari-
ants. Our systems-level analysis of rare genetic variants,
shared by affected individuals in families, and functional
analysis in zebrafish identified defects in calcium signal-
ing as a novel pathophysiological mechanism in CHD.
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